ASND
Ascendis Pharma A/s
$130.85
Earnings Summary
Revenue | $57.83Mn |
Net Profits | $-99.2Mn |
Net Profit Margins | -171.52% |
Highlights
Ascendis Pharma A/s’s revenue jumped 20.4% since last year same period to $57.83Mn in the Q3 2024. On a quarterly growth basis, Ascendis Pharma A/s has generated 60.66% jump in its revenue since last 3-months.
Ascendis Pharma A/s’s net profit jumped 38.85% since last year same period to $-99.2Mn in the Q3 2024. On a quarterly growth basis, Ascendis Pharma A/s has generated 9.31% jump in its net profits since last 3-months.
Ascendis Pharma A/s’s net profit margin jumped 49.21% since last year same period to -171.52% in the Q3 2024. On a quarterly growth basis, Ascendis Pharma A/s has generated 43.55% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Ascendis Pharma A/s post its latest quarter earnings
EPS Estimate Current Quarter | -1.89 |
EPS Estimate Current Year | -1.89 |
Highlights
Ascendis Pharma A/s’s earning per share (EPS) estimates for the current quarter stand at -1.89 - a -29.45% fall from last quarter’s estimates.
Ascendis Pharma A/s’s earning per share (EPS) estimates for the current year stand at -1.89.
Key Ratios
Key ratios of the Ascendis Pharma A/s post its Q3 2024 earnings
Earning Per Share (EPS) | -1.72 |
Highlights
Ascendis Pharma A/s’s earning per share (EPS) jumped 40.28% since last year same period to -1.72 in the Q3 2024. This indicates that the Ascendis Pharma A/s has generated 40.28% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-09-30 | -1.89 | -1.72 | 8.99% |
2024-05-02 | -1.5 | -2.3 | -53.33% |
₹0 US Stocks a/c Opening Fee